Lilly still breathing in inhaler pursuit
Pfizer Inc.’s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open
for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer’s troubles might cause
doctors and patients to sour on all inhaled insulin products.